Login
Companies $ABSI
$7.53 +$0.06 (0.74%) After hours
Absci Corp logo

Absci Corp

absci.com

What Do They Do?

Develops antibody therapeutics for patients and uses an AI drug-creation platform to support programs for biopharmaceutical partners.

How Do They Make Money?

Partners pay fees for drug-creation work upfront, when project milestones are reached, and throughout programs; future payments may also include development milestones and royalties on product sales.

FY2025 revenue

Who Are Their Customers?

Biopharmaceutical partners engage Absci for drug-creation collaborations and co-development programs using its platform.

Do Revenues Turn Into Profits?

No. It lost $115.2M in FY2025.

Operating income, FY2025
−4297% of revenue
▼ −10% (Loss) vs FY2024 (−$108.9M, −2402%)
Net income, FY2025
−4114% of revenue
▼ −12% (Loss) vs FY2024 (−$103.1M, −2274%)
Free cash flow, FY2025
−3358% of revenue
▼ −29% (Loss) vs FY2024 (−$72.8M, −1606%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −20%
vs $378K in Q3 FY2025
Net income
▼ −16% (Loss)
vs −$28.7M in Q3 FY2025

Shrinking. Revenue fell 41% in 4 years, from $4.8M in FY2021 to $2.8M in FY2025, about 13% a year.

Internal programs advance further The older report described an internal drug-discovery pipeline alongside partner work. The latest report says Absci plans to advance selected internally developed programs through clinical development and potential commercialization, while partnering or out-licensing others.

A sharper focus on antibodies The older report described a broad biologics platform that included cell-line development and new modalities. The latest report centers its platform and pipeline on antibody-based therapeutics.

Who Do They Compete With?

Competes with Hope Medicine, Veradermics, Pelage Pharmaceuticals, Cosmo Pharmaceuticals, Chugai Pharmaceuticals, GenSci, Merck, Roche/Roivant, Sanofi/Teva, Spyre, AbbVie, Xencor, Generate Biomedicines, Xaira Therapeutics, Recursion Pharmaceuticals, and Isomorphic Labs

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support